eGenesis September 2024 Series D Funding round

eGenesis, a biotechnology company focused on addressing the global organ shortage, has raised $191 million in a Series D funding round. Led by Lux Capital, the financing includes participation from ARCH Ventures, Khosla Ventures, and new investors such as DaVita and Eisai Innovation. The funds will be used to advance eGenesis' lead candidate, EGEN-2784, for kidney transplants, and to support pipeline programs and production scaling. CEO Mike Curtis highlighted the company’s progress in cross-species transplantation, aiming to provide a solution for organ failure with genetically engineered organs.